Laser photocoagulation superior to new drug for diabetic eye condition - NICE
This article was originally published in Clinica
Executive Summary
Laser photocoagulation should be retained as the technology of choice for the treatment of diabetic macular oedema (DMO), instead of Novartis’ Lucentis (ranibizumab), according to draft guidelines by the UK’s National Institute for Health and Clinical Excellence (NICE).